DE102017125335B4 - Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten - Google Patents
Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten Download PDFInfo
- Publication number
- DE102017125335B4 DE102017125335B4 DE102017125335.1A DE102017125335A DE102017125335B4 DE 102017125335 B4 DE102017125335 B4 DE 102017125335B4 DE 102017125335 A DE102017125335 A DE 102017125335A DE 102017125335 B4 DE102017125335 B4 DE 102017125335B4
- Authority
- DE
- Germany
- Prior art keywords
- amplicon
- seq
- cells
- methylation
- cpg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001616 monocyte Anatomy 0.000 title claims abstract description 68
- 108091093088 Amplicon Proteins 0.000 title claims abstract description 43
- 230000001973 epigenetic effect Effects 0.000 title description 5
- 210000002865 immune cell Anatomy 0.000 title description 4
- 239000003550 marker Substances 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 63
- 210000004027 cell Anatomy 0.000 claims abstract description 45
- 230000011987 methylation Effects 0.000 claims abstract description 29
- 238000007069 methylation reaction Methods 0.000 claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 230000017858 demethylation Effects 0.000 claims abstract description 5
- 238000010520 demethylation reaction Methods 0.000 claims abstract description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 33
- 108020004414 DNA Proteins 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 108091029523 CpG island Proteins 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 4
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 238000001369 bisulfite sequencing Methods 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 2
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000006862 enzymatic digestion Effects 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 28
- 229940104302 cytosine Drugs 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 230000007067 DNA methylation Effects 0.000 description 11
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 10
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000008836 DNA modification Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- BLQMCTXZEMGOJM-UHFFFAOYSA-N 5-carboxycytosine Chemical compound NC=1NC(=O)N=CC=1C(O)=O BLQMCTXZEMGOJM-UHFFFAOYSA-N 0.000 description 3
- FHSISDGOVSHJRW-UHFFFAOYSA-N 5-formylcytosine Chemical compound NC1=NC(=O)NC=C1C=O FHSISDGOVSHJRW-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004049 epigenetic modification Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 101150008740 cpg-1 gene Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000004918 Cartilage-hair hypoplasia Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108700029231 Developmental Genes Proteins 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 201000007142 Omenn syndrome Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 201000001322 T cell deficiency Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000006329 citrullination Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000007031 hydroxymethylation reaction Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 101150101567 pat-2 gene Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017125335.1A DE102017125335B4 (de) | 2017-10-27 | 2017-10-27 | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten |
| JP2020523795A JP2021502806A (ja) | 2017-10-27 | 2018-10-26 | 免疫細胞、特に非古典的単球の同定のためのエピジェネティックマーカーとしての単位複製配列領域 |
| CA3079477A CA3079477A1 (en) | 2017-10-27 | 2018-10-26 | Amplicon region as epigenetic marker for the identification of non-classical monocytes |
| CN201880068476.5A CN111247253A (zh) | 2017-10-27 | 2018-10-26 | 作为用于鉴定免疫细胞尤其是非典型单核细胞的表观遗传标记的扩增子区 |
| PCT/EP2018/079406 WO2019081707A1 (en) | 2017-10-27 | 2018-10-26 | AMPLICON REGION AS AN EPIGENETIC MARKER FOR THE IDENTIFICATION OF NON-CLASSIC MONOCYTES |
| AU2018356572A AU2018356572A1 (en) | 2017-10-27 | 2018-10-26 | Amplicon region as epigenetic marker for the identification of non-classical monocytes |
| EP18793655.4A EP3669001B1 (en) | 2017-10-27 | 2018-10-26 | Amplicon region as epigenetic marker for the identification of non-classical monocytes |
| US16/758,992 US11680294B2 (en) | 2017-10-27 | 2018-10-26 | Amplicon region as epigenetic marker for the identification of non-classical monocytes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017125335.1A DE102017125335B4 (de) | 2017-10-27 | 2017-10-27 | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE102017125335A1 DE102017125335A1 (de) | 2019-05-02 |
| DE102017125335B4 true DE102017125335B4 (de) | 2019-10-17 |
Family
ID=64024040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102017125335.1A Active DE102017125335B4 (de) | 2017-10-27 | 2017-10-27 | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11680294B2 (enExample) |
| EP (1) | EP3669001B1 (enExample) |
| JP (1) | JP2021502806A (enExample) |
| CN (1) | CN111247253A (enExample) |
| AU (1) | AU2018356572A1 (enExample) |
| CA (1) | CA3079477A1 (enExample) |
| DE (1) | DE102017125335B4 (enExample) |
| WO (1) | WO2019081707A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022191293A1 (ja) * | 2021-03-12 | 2022-09-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 全単球及びｃｄ１６陽性単球の割合の測定方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012162660A2 (en) | 2011-05-25 | 2012-11-29 | Brown University | Methods using dna methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107941681B (zh) * | 2013-04-19 | 2021-07-30 | 艾皮恩蒂斯有限公司 | 鉴定生物样品中定量细胞组成的方法 |
| BR112015029299A2 (pt) * | 2013-05-22 | 2017-07-25 | Yeda Res & Dev | subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares |
| GB201516975D0 (en) * | 2015-09-25 | 2015-11-11 | Epiontis Gmbh | PARK2 as epigenetic marker for the identification of immune cells, in particular monocytes |
-
2017
- 2017-10-27 DE DE102017125335.1A patent/DE102017125335B4/de active Active
-
2018
- 2018-10-26 WO PCT/EP2018/079406 patent/WO2019081707A1/en not_active Ceased
- 2018-10-26 CN CN201880068476.5A patent/CN111247253A/zh not_active Withdrawn
- 2018-10-26 CA CA3079477A patent/CA3079477A1/en active Pending
- 2018-10-26 JP JP2020523795A patent/JP2021502806A/ja active Pending
- 2018-10-26 EP EP18793655.4A patent/EP3669001B1/en active Active
- 2018-10-26 US US16/758,992 patent/US11680294B2/en active Active
- 2018-10-26 AU AU2018356572A patent/AU2018356572A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012162660A2 (en) | 2011-05-25 | 2012-11-29 | Brown University | Methods using dna methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies |
Non-Patent Citations (10)
| Title |
|---|
| Accomando et al. (in: Accomando et al. Quantitative reconstruction of leukocyte subsets using DNA methylation. Genome Biol. 2014 Mar 5;15(3) |
| Antequera und Bird, Proc Natl Acad Sci USA 90: 11995-9, 1993 |
| Esteller, Oncogene 21:5427-5440, 2002 |
| Illingworth et al. (in Illingworth et al. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol. 2008 Jan;6(1):e22. doi: 10.1371/journal.pbio.0060022) |
| Jones und Laird, Nature Genetics 21:163-167, 1999 |
| Kristensen und Hansen PCR-Based Methods for Detecting Single-Locus DNA Methylation Biomarkers in Cancer Diagnostics, Prognostics, and Response to Treatment Clinical Chemistry 55:8 1471-1483 (2009) |
| Laird, Nature Reviews/Cancer 3:253-266, 2003 |
| LIU, Y. [u.a.]: Blood monocyte transcriptome and epigenome analyses reveal loci associated with human atherosclerosis. Nat. Commun. (elektronisch veröffentlicht 30.08.2017) 8 (1):393, Seiten 1-12 * |
| Michael J. Booth et al. Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-Base Resolution Science 18 May 2012, Vol. 336 no. 6083 pp. 934-937 |
| Zawada et al. (in: Zawada et al. DNA methylation profiling reveals differences in the 3 human monocyte subsets and identifies uremia to induce DNA methylation changes during differentiation. Epigenetics. 2016 Apr 2;11(4):259-72 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3079477A1 (en) | 2019-05-02 |
| US20200340053A1 (en) | 2020-10-29 |
| AU2018356572A1 (en) | 2020-04-23 |
| CN111247253A (zh) | 2020-06-05 |
| JP2021502806A (ja) | 2021-02-04 |
| EP3669001B1 (en) | 2024-07-17 |
| US11680294B2 (en) | 2023-06-20 |
| DE102017125335A1 (de) | 2019-05-02 |
| WO2019081707A1 (en) | 2019-05-02 |
| EP3669001A1 (en) | 2020-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108026590B (zh) | Park2作为用于鉴定免疫细胞特别是单核细胞的表观遗传标志物 | |
| CN108026577B (zh) | Mvd作为用于鉴定免疫细胞特别是cd56+nk细胞的表观遗传标志物 | |
| DE102017125013B4 (de) | MCC als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere basophiler Granulozyten | |
| DE102017125335B4 (de) | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten | |
| DE102017125150B4 (de) | Endosialin (CD248) als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere naïver CD8+ T-Zellen | |
| DE102023114016B3 (de) | LAG3 als epigenetischer Marker für die Identifizierung von Immunzellen | |
| DE102023114004B3 (de) | GATA 3 als epigenetischer Marker zur Identifizierung von Immunzellen | |
| DE102023114015B3 (de) | ITGA4 als epigenetischer Marker für die Identifizierung von Immunzellen | |
| DE102023114008B3 (de) | CRTH2 (PTGDR2) als epigenetischer Marker zur Identifizierung von Immunzellen | |
| DE102020108560B4 (de) | CBX6 als epigenetischer Marker für die Identifizierung von Immunzellen, insbesondere Gedächtnis-B-Zellen | |
| DE102017125019B4 (de) | PDCD1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere PD1+ Zellen | |
| DE102017126248B4 (de) | ERGIC1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesonderemonozytischem myeloid-abgeleiteten Suppressor-Zellen (mMDSCs) | |
| DE102020111423B4 (de) | MYH11/NDE1 Region als epigenetischer Marker für die Identifizierung von Endothel-Vorläuferzellen (EPCs) | |
| DE102018112644B4 (de) | CXCR3 als epigenetischer Marker zur Identifizierung von inflammatorischen Immunzellen, insbesondere CD8+ Gedächnis-T-Zellen | |
| CA3080060C (en) | Pdcd1 as epigenetic marker for the identification of immune cells, in particular pd1+ cells | |
| DE102015121969A1 (de) | Verfahren zur Verbesserung der Diagnose von Telomererkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R012 | Request for examination validly filed | ||
| R016 | Response to examination communication | ||
| R018 | Grant decision by examination section/examining division | ||
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: C12Q0001680000 Ipc: C12Q0001688100 |
|
| R020 | Patent grant now final | ||
| R082 | Change of representative |
Representative=s name: KRAUSS, JAN, DR., DE |